Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer - Scorecard - MDSpire
Advertisement
Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer
Clinical Scorecard: Evaluating the Necessity of Complete Adherence: Real-World Outcomes of Perioperative Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer
At a Glance
Category
Detail
Condition
Key Mechanisms
Neoadjuvant chemoimmunotherapy followed by surgery and adjuvant immunotherapy.
Target Population
Care Setting
Key Highlights
No significant differences in recurrence-free survival or overall survival between completed and non-completed groups.
Positive pathological nodal status was an independent predictor of recurrence.
Higher incidence of any-grade adverse events in the completed group, but no significant increase in Grade 3/4 AEs.
Guideline-Based Recommendations
Diagnosis
Management
Neoadjuvant chemoimmunotherapy followed by surgery and one year of adjuvant immunotherapy is recommended.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients aged 18-75 years with resectable stage IB-IIIB NSCLC.
Completion of the full regimen did not show a significant survival benefit.
Clinical Best Practices
Utilize a multidisciplinary team for treatment strategy decisions.
Consider patient age and ECOG performance status when assessing treatment completion benefits.
